Pharmaceutical Executive
Hungary is fast staking a reputation for itself as one of Central and Eastern Europe’s most dynamic economies. A major factor has been pharmaceuticals, where Hungary’s history of research and production is reflected today in an attractive pharma investment landscape and the presence of home-grown success stories.
Hungary is fast staking a reputation for itself as one of Central and Eastern Europe (CEE)’s most dynamic economies. Thanks to increased European Union (EU) funding, higher EU demand for its exports, and a rebound in domestic household consumption, the country achieved year-on-year GDP growth of 4.8 percent in 2019. GDP per capita stands at USD 16,500 today, significantly above the pre-global financial crisis high of USD 14,000.
A major factor behind this economic growth is pharmaceuticals, which account for 7.5 percent of Hungary’s GDP and have long been a national flagship industry. As Dr. György Bagdy, professor and former vice rector at Semmelweis University, notes, “after the Second World War, the eastern bloc countries were given special commitments by the Soviet Union, and Hungary was bestowed drug research and discovery responsibility.”
This history of pharmacological research and production is reflected today in an attractive pharma investment landscape and the presence of home-grown success stories such as Gedeon Richter and Egis on the international scene. Around 60 companies are licensed to manufacture human medicinal products in Hungary, making it one of Eastern Europe’s leading pharmaceutical manufacturers, and medical and pharmaceutical goods account for 4.9% of the nation’s total exports, the highest percentage in the CEE region.
To view the full article on Hungary's pharma and healthcare markets, produced by Focus Reports and featured in Pharm Exec's February 2020 issue, click
here(cycle down to page 36).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Recent Developments in Pharmaceutical Validation
November 1st 2024Explore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape.